Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average recommendation of “Buy” by the twenty-three brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $256.42.
Several equities research analysts have recently issued reports on ILMN shares. Morgan Stanley increased their price objective on shares of Illumina from $180.00 to $195.00 and gave the stock an “underweight” rating in a research report on Thursday, May 31st. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Monday, April 16th. Barclays increased their price objective on shares of Illumina from $215.00 to $235.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 25th. Finally, ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 26th.
In other news, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $288.45, for a total value of $144,225.00. Following the transaction, the director now directly owns 6,639 shares in the company, valued at approximately $1,915,019.55. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 116 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $230.91, for a total transaction of $26,785.56. Following the completion of the transaction, the senior vice president now owns 7,875 shares in the company, valued at $1,818,416.25. The disclosure for this sale can be found here. Insiders have sold a total of 39,271 shares of company stock worth $10,483,503 over the last quarter. 0.54% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Illumina by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,580,736 shares of the life sciences company’s stock worth $344,665,000 after buying an additional 55,888 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Illumina by 3.0% in the 4th quarter. TIAA CREF Investment Management LLC now owns 1,544,831 shares of the life sciences company’s stock worth $337,530,000 after buying an additional 44,816 shares during the last quarter. Jackson Square Partners LLC lifted its position in shares of Illumina by 263.0% in the 4th quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock worth $226,017,000 after buying an additional 749,468 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of Illumina by 75.9% in the 1st quarter. Prudential Financial Inc. now owns 762,186 shares of the life sciences company’s stock worth $180,196,000 after buying an additional 328,886 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Illumina by 19.2% in the 1st quarter. American Century Companies Inc. now owns 761,796 shares of the life sciences company’s stock worth $180,104,000 after buying an additional 122,612 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.
Illumina opened at $279.29 on Tuesday, MarketBeat Ratings reports. Illumina has a 52-week low of $167.98 and a 52-week high of $293.15. The firm has a market capitalization of $41.06 billion, a PE ratio of 69.82, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The company had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. During the same quarter in the prior year, the business earned $0.64 earnings per share. The business’s quarterly revenue was up 30.8% compared to the same quarter last year. research analysts anticipate that Illumina will post 4.86 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.